


## WHAT IS CLAIMED IS:

1. A pharmaceutical dosage form comprising (a) at least one agent effective in treatment of sexual dysfunction having a molecular weight, excluding counterions, not greater than 250, in a therapeutically or sexual-stimulatorily effective total amount, and (b) at least one pharmaceutically acceptable excipient; the dosage form being adapted for delivery by a route of administration that entails interaction with the organs of taste yet having acceptable organoleptic properties.
2. The dosage form of Claim 1 wherein the at least one agent has a molecular weight, excluding counterions, not greater than 235.
3. The dosage form of Claim 1 wherein the at least one agent has a molecular weight, excluding counterions, not greater than 220.
4. The dosage form of Claim 1 wherein the at least one agent has a solubility in water at 20-25°C of at least about 10 g/l.
5. The dosage form of Claim 1 wherein the at least one agent is a compound having the formula




wherein X is O or S; or a pharmaceutically acceptable salt thereof.

6. The dosage form of Claim 1 wherein the total amount of the at least one agent per dose is lower than an amount causing significant side-effects.
7. The dosage form of Claim 1 wherein the therapeutic agent is sumanirole or a salt thereof and is present in an amount of about 0.05 mg to about 5 mg per dose.
8. The dosage form of Claim 1 wherein the therapeutic agent is (*R*)-5,6-dihydro-5-(methylamino)-4H-imidazo[4,5-*ij*]-quinoline-2(1H)-thione or a salt thereof and is present in an amount of about 0.05 mg to about 5 mg per dose.

9. The dosage form of Claim 8 wherein the therapeutic agent is present in an amount of about 0.1 to about 3 mg per dose.
10. The dosage form of Claim 1 that is adapted for a route of administration selected from oral, buccal, sublingual, nasal and tracheal routes.
- 5 11. The dosage form of Claim 1 that is selected from
- (a) buccal and sublingual tablets;
  - (b) mucoadhesive films;
  - (c) oral strips;
  - (d) chewable tablets;
  - 10 (e) rapidly disintegrating oral dosage forms;
  - (f) lozenges and pastilles;
  - (g) breath-fresheners;
  - (h) chewing gums;
  - (i) lollipops and popsicles;
  - 15 (j) food adjuncts;
  - (k) candies and chocolates;
  - (l) periodontal gels;
  - (m) mouthwashes;
  - (n) oral and nasal drops and sprays;
  - 20 (o) dosage forms adapted for inhalation as an aerosol or vapor;
  - (p) elixirs, solutions, suspensions and other orally administered liquid dosage forms;
  - (q) powders, granules and tablets for dissolution or dispersion in water prior to oral administration; and
  - 25 (r) effervescent tablets and granules.
12. The dosage form of Claim 1 that is adapted for discreet self-administration.
13. The dosage form of Claim 1 that is adapted for nasal administration.
14. The dosage form of Claim 13 that is formulated as a nasal spray solution.
15. The dosage form of Claim 1 that is adapted for oral, buccal or sublingual administration.
- 30

16. The dosage form of Claim 15 that dissolves in the mouth without need for drinking water or other fluid.
17. The dosage form of Claim 15 that is a breath-freshening pastille.
18. The dosage form of Claim 15 that is a chewing gum.
- 5 19. The dosage form of Claim 15 that is a sublingual tablet.
20. The dosage form of Claim 15 that is a mucoadhesive film.
21. The dosage form of Claim 15 that is an oral strip.
22. The dosage form of Claim 15 that is an oral fast-melt tablet.
23. A pharmaceutical dosage form comprising (a) a therapeutically or sexual-stimulatorily effective amount of about 0.1 mg to about 10 mg per dose of a  
10 therapeutic agent that comprises at least one compound of formula



or a pharmaceutically acceptable water-soluble salt thereof, said compound or salt thereof being water-soluble, wherein

- 15  $R^1$ ,  $R^2$  and  $R^3$  are the same or different and are H,  $C_{1-6}$  alkyl (optionally phenyl substituted),  $C_{3-5}$  alkenyl or alkynyl or  $C_{3-10}$  cycloalkyl, or where  $R^3$  is as above and  $R^1$  and  $R^2$  are cyclized with the attached N atom to form pyrrolidinyl, piperidinyl, morpholinyl, 4-methylpiperazinyl or imidazolyl groups;
- 20 X is H, F, Cl, Br, I, OH,  $C_{1-6}$  alkyl or alkoxy, CN, carboxamide, carboxyl or ( $C_{1-6}$  alkyl)carbonyl;  
A is CH,  $CH_2$ , CHF, CHCl, CHBr, CHI,  $CHCH_3$ , C=O, C=S,  $CSCH_3$ , C=NH,  $CNH_2$ ,  $CNHCH_3$ ,  $CNHCOOCH_3$ ,  $CNHCN$ ,  $SO_2$  or N;  
B is CH,  $CH_2$ , CHF, CHCl, CHBr, CHI, C=O, N, NH or  $NCH_3$ , and n is 0 or  
25 1; and

D is CH, CH<sub>2</sub>, CHF, CHCl, CHBr, CHI, C=O, O, N, NH or NCH<sub>3</sub>;  
 and (b) one or more pharmaceutically acceptable excipients; the dosage form  
 being adapted for delivery by a route of administration that entails interaction  
 with the organs of taste yet having acceptable organoleptic properties.

- 5    24. The dosage form of Claim 23 wherein the water-soluble compound or salt  
       thereof has a solubility in water at 20-25°C of at least about 10 g/l.
25. The dosage form of Claim 23 wherein the water-soluble compound or salt  
       thereof is disclosed generically or specifically in U.S. Patent No. 5,273,975.
- 10    26. The dosage form of Claim 23 that is adapted for a route of administration  
       selected from oral, buccal, sublingual, nasal and tracheal routes.
27. The dosage form of Claim 23 that is selected from
  - (a) buccal and sublingual tablets;
  - (b) mucoadhesive films;
  - (c) oral strips;
  - 15    (d) chewable tablets;
  - (e) rapidly disintegrating oral dosage forms;
  - (f) lozenges and pastilles;
  - (g) breath-fresheners;
  - (h) chewing gums;
  - 20    (i) lollipops and popsicles;
  - (j) food adjuncts;
  - (k) candies and chocolates;
  - (l) periodontal gels;
  - (m) mouthwashes;
  - 25    (n) oral and nasal drops and sprays;
  - (o) dosage forms adapted for inhalation as an aerosol or vapor;
  - (p) elixirs, solutions, suspensions and other orally administered liquid dosage  
       forms;
  - (q) powders, granules and tablets for dissolution or dispersion in water prior to  
       oral administration; and
  - 30    (r) effervescent tablets and granules.

28. The dosage form of Claim 23 that is adapted for discreet self-administration.
29. The dosage form of Claim 23 that is adapted for nasal administration.
30. The dosage form of Claim 29 that is formulated as a nasal spray solution.
31. The dosage form of Claim 23 that is adapted for oral, buccal or sublingual  
5 administration.
32. The dosage form of Claim 31 that dissolves in the mouth without need for  
drinking water or other fluid.
33. The dosage form of Claim 31 that is a breath-freshening pastille.
34. The dosage form of Claim 31 that is a chewing gum.
- 10 35. The dosage form of Claim 31 that is a sublingual tablet.
36. The dosage form of Claim 31 that is a mucoadhesive film.
37. The dosage form of Claim 31 that is an oral strip.
38. The dosage form of Claim 31 that is an oral fast-melt tablet.
- 15 39. A method of treating sexual dysfunction in a subject comprising intraoral  
administration of a dosage form of Claim 1 to the subject, less than about 1 hour  
prior to sexual activity.
40. A method of treating sexual dysfunction in a subject comprising intraoral  
administration of a dosage form of Claim 23 to the subject, less than about 1  
hour prior to sexual activity.
- 20 41. A method of enhancing sexual desire, interest or performance in a subject  
comprising intraoral administration of a dosage form of Claim 1 to the subject,  
less than about 1 hour prior to sexual activity.
42. A method of enhancing sexual desire, interest or performance in a subject  
comprising intraoral administration of a dosage form of Claim 23 to the subject,  
25 less than about 1 hour prior to sexual activity.